Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, |
RCV000857256 | SCV000999845 | likely pathogenic | Lysosomal acid lipase deficiency | 2019-06-01 | criteria provided, single submitter | research | |
Prevention |
RCV004528320 | SCV004109187 | uncertain significance | LIPA-related disorder | 2023-03-14 | criteria provided, single submitter | clinical testing | The LIPA c.974C>T variant is predicted to result in the amino acid substitution p.Pro325Leu. This variant was reported in one individual with lysosomal acid lipase deficiency participating in clinical trial (Del Angel et al. 2019. PubMed ID: 31180157). In vitro functional studies showed that this variant results in enzymatic activity of ab out 7-8% of wild type activity (Del Angel et al. 2019. PubMed ID: 31180157 Table S1). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |